Curiosity and online activity can be mistaken for misconduct by vigilant algorithms. These algorithms protect digital platforms from strain, fraud, and misuse but may misinterpret
Category: News
What Happens to Your Genetic Data if 23andMe Goes Bankrupt?
23andMe has filed for Chapter 11 bankruptcy, raising concerns about the handling of genetic data from its 15 million customers. The House Committee on Energy
China’s Biotech Surge: A New Era of Global Power Dynamics
China leads a transformative biotechnology revolution, integrating it into national strategy and global ambitions. The U.S. National Security Commission on Emerging Biotechnology warns of China’s
The Agricultural Biotech Boom: Why It’s Poised to Redefine Our Food Systems
The agricultural biotechnology market is expected to grow significantly, from USD 43.2 billion in 2025 to USD 79.7 billion by 2032. Population growth to 9
Analysts Bet on Vir Biotechnology Amid Shifting Market Sentiments
Vir Biotechnology is a prominent figure in the biotech sector, drawing both excitement and caution among analysts. Analyst price targets for Vir vary widely, from
The Tension Unfolding in Europe’s Biotech Arena: Balancing Innovation and Biosecurity
Europe’s biotech sector, controlling 12% of the global market, is focused on innovation and biosecurity excellence. Key discussions highlight the need to balance groundbreaking biotech
The Surprising Legacy Behind Boston’s Rise as a Biotech Powerhouse
The 1975 Asilomar Conference set a benchmark for safety in recombinant DNA research, pivotal for modern biotech regulation. Cambridge, MA, became a biotech hub in
Biotechnology: The New Frontier in the U.S.-China Tech Rivalry
Biotechnology is central to U.S. national strategy, representing a crucial battleground in the competition with China. The National Security Commission on Emerging Biotechnology’s report urges
Why Canada’s Billion-Dollar Biotech Discoveries Aren’t Benefitting Canadians
Canada is a leader in medical innovation but often misses out on economic benefits due to inadequate commercialization. Historical examples, like insulin’s discovery, highlight Canada’s
The Biotech Bust: How Sana’s Lofty Promises Led to a Legal Showdown
Sana Biotechnology faced legal challenges due to alleged transparency issues with investors. The company initially showcased promising projects, SC291, SC379, and SG299, targeting B-cell malignancies